GlycoPharma Holding ApS: Financial statements 2025
CVR: 39691558
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
GlycoPharma Holding ApS (CVR 39691558) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -12,525 and a net result of DKK -12,441 compared with DKK -15,360 the year before. Equity in the 2025 report amounted to DKK 684,140. The solvency ratio was 85.2%.
- Gross Profit
- DKK -12,525
- Profit/Loss
- DKK -12,441
- Equity
- DKK 684,140
- Total Assets
- DKK 802,652
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -13K | -12K | 684K | 0 |
| 2024 | - | -16K | -15K | 697K | 0 |
| 2023 | - | -14K | -14K | 584K | - |
| 2022 | - | -8K | -7K | 407K | - |
| 2021 | - | -12K | -8K | 414K | - |
Official annual report
How creditworthy is GlycoPharma Holding ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout GlycoPharma Holding ApS
GlycoPharma Holding ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Anders Boysen. The company's owners include SCIENCE VENTURES DENMARK A/S, Boysen Bio ApS and Zahle Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -12,525 and a net result of DKK -12,441 compared with DKK -15,360 the year before. Equity in the 2025 report amounted to DKK 684,140.